open access

Vol 27, No 4 (2023)
Original paper
Published online: 2023-06-26
Get Citation

Prevalence of the metabolic syndrome in Poland based on the new 2022 definition

Gilbert Artur Baćmaga1, Natalia Dąbrowska1, Alicja Cicha-Mikołajczyk1, Piotr Bandosz2, Krystyna Kozakiewicz3, Andrzej Pająk4, Magdalena Agnieszka Kwaśniewska5, Arkadiusz Niklas6, Aleksander Prejbisz1, Piotr Dobrowolski1
·
Arterial Hypertension 2023;27(4):215-222.
Affiliations
  1. Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, National Institute of Cardiology, Warsaw, Poland
  2. Department of Arterial Hypertension and Diabetology, Medical University of Gdańsk, Gdańsk, Poland
  3. 3rd Department of Cardiology, Medical University of Silesia, Katowice, Poland
  4. Department of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland
  5. Department of Social and Preventive Medicine, Medical University of Lodz, Łódź, Poland
  6. Department of Hypertension, Angiology and Internal Disease, Poznan University of Medical Science, Poznań, Poland

open access

Vol 27, No 4 (2023)
ORIGINAL PAPERS
Published online: 2023-06-26

Abstract

Background: Metabolic syndrome (MS) is a cluster of cardiovascular risk factors. In 2022 Polish experts proposed a new definition of MS. The aim of this study was to analyze the frequency of the MS based on the WOBASZ II cohort (2013–2014) and compare it to that based on the previous definition.

Material and methods: The WOBASZ II study was conducted on a sample of 6170 Polish adults. The 2022 definition of MS includes: abdominal obesity, hypertension, impaired glucose metabolism, atherogenic dyslipidemia; MS is diagnosed if abdominal obesity and at least two other factors are present. The old definition based on the 2009 Joint Interim Statement included: abdominal obesity, elevated blood pressure, impaired glucose metabolism, hypertriglyceridemia, low high-density lipoprotein cholesterol; MS was diagnosed if at least three criteria were met.

Results: The prevalence of the MS in the WOBASZ II cohort according to the new definition was 31.7%. Compared to the previous definition the prevalence of MS decreased significantly in men (42.8% vs. 29.2%; p < 0.0001) and no change was observed in women (34.6% vs. 33.7%; p = 0.19). Due to the change in criteria prevalence of the obesity component decreased in the Polish population from 65.9% to 44.0%; p < 0.0001. Atherogenic dyslipidemia became the most prevalent component (67.6%, an increase from 42.6%; p < 0.0001). High normal blood pressure/hypertension and diabetes/pre-diabetes components were present in 60.9% and 32.6% of respondents.

Conclusions: Despite that the estimate of the prevalence of MS according to the new definition is lower as compared to the previous definition, MS and its components remain widespread in the Polish population.

Abstract

Background: Metabolic syndrome (MS) is a cluster of cardiovascular risk factors. In 2022 Polish experts proposed a new definition of MS. The aim of this study was to analyze the frequency of the MS based on the WOBASZ II cohort (2013–2014) and compare it to that based on the previous definition.

Material and methods: The WOBASZ II study was conducted on a sample of 6170 Polish adults. The 2022 definition of MS includes: abdominal obesity, hypertension, impaired glucose metabolism, atherogenic dyslipidemia; MS is diagnosed if abdominal obesity and at least two other factors are present. The old definition based on the 2009 Joint Interim Statement included: abdominal obesity, elevated blood pressure, impaired glucose metabolism, hypertriglyceridemia, low high-density lipoprotein cholesterol; MS was diagnosed if at least three criteria were met.

Results: The prevalence of the MS in the WOBASZ II cohort according to the new definition was 31.7%. Compared to the previous definition the prevalence of MS decreased significantly in men (42.8% vs. 29.2%; p < 0.0001) and no change was observed in women (34.6% vs. 33.7%; p = 0.19). Due to the change in criteria prevalence of the obesity component decreased in the Polish population from 65.9% to 44.0%; p < 0.0001. Atherogenic dyslipidemia became the most prevalent component (67.6%, an increase from 42.6%; p < 0.0001). High normal blood pressure/hypertension and diabetes/pre-diabetes components were present in 60.9% and 32.6% of respondents.

Conclusions: Despite that the estimate of the prevalence of MS according to the new definition is lower as compared to the previous definition, MS and its components remain widespread in the Polish population.

Get Citation

Keywords

metabolic syndrome; abdominal obesity; hypertension; hyperglycemia; dyslipidemia; cardiometabolic risk factors

About this article
Title

Prevalence of the metabolic syndrome in Poland based on the new 2022 definition

Journal

Arterial Hypertension

Issue

Vol 27, No 4 (2023)

Article type

Original paper

Pages

215-222

Published online

2023-06-26

Page views

745

Article views/downloads

199

DOI

10.5603/AH.a2023.0016

Bibliographic record

Arterial Hypertension 2023;27(4):215-222.

Keywords

metabolic syndrome
abdominal obesity
hypertension
hyperglycemia
dyslipidemia
cardiometabolic risk factors

Authors

Gilbert Artur Baćmaga
Natalia Dąbrowska
Alicja Cicha-Mikołajczyk
Piotr Bandosz
Krystyna Kozakiewicz
Andrzej Pająk
Magdalena Agnieszka Kwaśniewska
Arkadiusz Niklas
Aleksander Prejbisz
Piotr Dobrowolski

References (21)
  1. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
  2. Statistics Poland. Demographic situation in Poland up to 2020 Death and mortality. https://stat.gov.pl/obszary-tematyczne/ludnosc/ludnosc/sytuacja-demograficzna-polski-do-2020-roku-zgony-i-umieralnosc,40,1.html (10.05.2023).
  3. Dobrowolski P, Prejbisz A, Kuryłowicz A, et al. Metabolic syndrome — a new definition and management guidelines. Arterial Hypertension. 2022; 26(3): 99–121.
  4. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention, Hational Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640–1645.
  5. Drygas W, Niklas AA, Piwońska A, et al. Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. Kardiol Pol. 2016; 74(7): 681–690.
  6. World Health Organization . STEPS Manual. WHO, Geneva : Word.
  7. Heath Organization 2014. Noncommunicable Disease Surveillance, Monitoring and Reporting. https://www who int/teams/noncommunicable-diseases/surveillance/systems-tools/steps/manuals (accessed 10 05 (10.05.2023).
  8. Tolonen H. (ed.). EHES Manual. Part A. Planning and preparation of the survey. 2nd ed. National Institute for Health and Welfare, 2016, Directions 2016_13. http://urn.fi/URN:ISBN:978-952-302-700-8 (10.05.2023).
  9. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007; 92(2): 399–404.
  10. Sommer A, Twig G. The Impact of Childhood and Adolescent Obesity on Cardiovascular Risk in Adulthood: a Systematic Review. Curr Diab Rep. 2018; 18(10): 91.
  11. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
  12. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012; 307(12): 1302–1309.
  13. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021; 17(6): 1447–1547.
  14. Solnica B, Sygitowicz G, Sitkiewicz D, et al. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2020; 16(2): 237–252.
  15. Bandosz P, O'Flaherty M, Rutkowski M, et al. A victory for statins or a defeat for diet policies? Cholesterol falls in Poland in the past decade: A modeling study. Int J Cardiol. 2015; 185: 313–319.
  16. American Diabetes Association Professional Practice Committee. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S17–S38.
  17. Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, et al. 2022 Guidelines on the management of patients with diabetes. A position of Diabetes Poland. Current Topics in Diabetes. 2022; 2(1).
  18. Hirode G, Wong RJ. Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA. 2020; 323(24): 2526–2528.
  19. de Siqueira Valadares LT, de Souza LS, Salgado Júnior VA, et al. Prevalence of metabolic syndrome in Brazilian adults in the last 10 years: a systematic review and meta-analysis. BMC Public Health. 2022; 22(1): 327.
  20. Li Ri, Li W, Lun Z, et al. Prevalence of metabolic syndrome in Mainland China: a meta-analysis of published studies. BMC Public Health. 2016; 16: 296.
  21. Ansarimoghaddam A, Adineh HA, Zareban I, et al. Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies. Diabetes Metab Syndr. 2018; 12(2): 195–201.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl